Page last updated: 2024-11-07
aldosterone and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
aldosterone has been researched along with Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted in 2 studies
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| " Midodrine and octreotide were dosed to obtain a stable increase of at least 15 mm Hg of mean arterial pressure." | 6.69 | Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. ( Amodio, P; Angeli, P; Caregaro, L; Craighero, R; Gatta, A; Gerunda, G; Maffei-Faccioli, A; Merenda, R; Roner, P; Sticca, A; Volpin, R, 1999) |
| " Midodrine and octreotide were dosed to obtain a stable increase of at least 15 mm Hg of mean arterial pressure." | 2.69 | Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. ( Amodio, P; Angeli, P; Caregaro, L; Craighero, R; Gatta, A; Gerunda, G; Maffei-Faccioli, A; Merenda, R; Roner, P; Sticca, A; Volpin, R, 1999) |
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Montes-de-Oca, M | 1 |
| Blanco, MJ | 1 |
| Marquez, M | 1 |
| Soto, MJ | 1 |
| Fernandez-Gutiérrez, C | 1 |
| Rodriguez-Ramos, C | 1 |
| Giron-Gonzalez, JA | 1 |
| Angeli, P | 1 |
| Volpin, R | 1 |
| Gerunda, G | 1 |
| Craighero, R | 1 |
| Roner, P | 1 |
| Merenda, R | 1 |
| Amodio, P | 1 |
| Sticca, A | 1 |
| Caregaro, L | 1 |
| Maffei-Faccioli, A | 1 |
| Gatta, A | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Vasoconstrictors as Alternatives to Albumin After Large Volume Paracentesis in Cirrhosis[NCT00108355] | Phase 4 | 29 participants (Actual) | Interventional | 2003-12-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Development of Post-paracentesis Circulatory Dysfunction (PCD)
Defined as an increase in Plasma Renin Activity (PRA) by >50% from baseline to a level > 4 ng/mL/h at post-paracentesis day (NCT00108355)
Timeframe: 6 days after paracentesis
| Intervention | participants (Number) |
|---|
| Albumin (Control Group) | 2 |
| Vasoconstrictor (Treatment Group) | 2 |
Time to Recurrence of Ascites.
Comparison between Albumin (Control group) and Vasoconstrictor (Treatment group) (NCT00108355)
Timeframe: Variable depending on the patient, average 10 days
| Intervention | days (Median) |
|---|
| Albumin (Control Group) | 10 |
| Vasoconstrictor (Treatment Group) | 8 |
Trials
1 trial available for aldosterone and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
Other Studies
1 other study available for aldosterone and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted